Provided by Tiger Trade Technology Pte. Ltd.

Xencor

26.06
-2.8200-9.76%
Post-market: 26.05-0.0118-0.05%19:30 EDT
Volume:2.05M
Turnover:54.17M
Market Cap:1.93B
PE:-11.97
High:28.97
Open:28.97
Low:25.81
Close:28.88
52wk High:30.61
52wk Low:7.83
Shares:74.13M
Float Shares:54.25M
Volume Ratio:1.46
T/O Rate:3.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1768
EPS(LYR):-1.2400
ROE:-29.07%
ROA:-16.83%
PB:3.84
PE(LYR):-21.02

Loading ...

Xencor Q2 EPS USD -0.29

Reuters
·
Aug 06

Xencor participates in a conference call with Cantor

TIPRANKS
·
Aug 04

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

TIPRANKS
·
Aug 04

Xencor Expands Plamotamab Into Rheumatoid Arthritis: What Early Trial Progress Means for Investors

TIPRANKS
·
Aug 04

Xencor Shares Rise After Settlement Deal With Alexion

MT Newswires Live
·
Jul 31

Xencor Price Target Maintained with a $26.00/Share by Wedbush

Dow Jones
·
Jul 30

Xencor to receive $105M from Alexion to resolve Ultomiris royalty matter

TIPRANKS
·
Jul 30

Xencor Settles Ultomiris U.S. Royalty Dispute with Alexion for USD 105 Million

Reuters
·
Jul 30

Xencor - First $52.50 Mln Payment Expected August 2026; Second Payment Due One Year Later

THOMSON REUTERS
·
Jul 30

Xencor - to Continue Receiving Royalties on Ex-U.S. Ultomiris Sales

THOMSON REUTERS
·
Jul 30

Xencor to Receive $105 Million from Alexion to Resolve Ultomiris® U.S. Royalty Matter

THOMSON REUTERS
·
Jul 30

Wedbush Reaffirms Their Buy Rating on Xencor (XNCR)

TIPRANKS
·
Jul 22

Xencor Inc : Leerink Partners Assumes Coverage with Outperform Rating; Target Price $29

THOMSON REUTERS
·
Jul 22

Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story?

Simply Wall St.
·
Jul 19

Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

MT Newswires Live
·
Jul 18

Xencor to Present Phase 1 Xmab819 Data in Advanced Kidney Cancer at ESMO 2026

Reuters
·
Jul 17

Xencor Announces Proffered Paper Oral Presentation at Esmo 2026 for Phase 1 Clinical Study of Xmab819 in Advanced Clear Cell Renal Cell Carcinoma

THOMSON REUTERS
·
Jul 17

Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain?

Simply Wall St.
·
Jul 11

Xencor price target lowered to $27 from $29 at Truist

TIPRANKS
·
Jul 07

Xencor is Maintained at Buy by Truist Securities

Dow Jones
·
Jul 07